Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Amy C Moreno, Erin E Watson, Laia Humbert-Vidan, Douglas E Peterson, Lisanne V van Dijk, Teresa Guerrero Urbano, Lisa Van den Bosch, Andrew J Hope, Matthew S Katz, Frank J P Hoebers, Ruth A Aponte Wesson, James E Bates, Paolo Bossi, Adeyinka F Dayo, Mélanie Doré, Eduardo Rodrigues Fregnani, Thomas J Galloway, Daphna Y Gelblum, Issa A Hanna, Christina E Henson, Sudarat Kiat-Amnuay, Anke Korfage, Nancy Y Lee, Carol M Lewis, Charlotte Duch Lynggaard, Antti A Mäkitie, Marco Magalhaes, Yvonne M Mowery, Carles Muñoz-Montplet, Jeffrey N Myers, Ester Orlandi, Jaymit Patel, Jillian M Rigert, Deborah Saunders, Jonathan D Schoenfeld, Ugur Selek, Efsun Somay, Vinita Takiar, Juliette Thariat, Gerda M Verduijn, Alessandro Villa, Nick West, Max J H Witjes, Alex Won, Mark E Wong, Christopher M K L Yao, Simon W Young, Kamal Al-Eryani, Carly E A Barbon, Doke J M Buurman, François J Dieleman, Theresa M Hofstede, Abdul Ahad Khan, Adegbenga O Otun, John C Robinson, Lauren Hum, Jorgen Johansen, Rajesh Lalla, Alexander Lin, Vinod Patel, Richard J Shaw, Mark S Chambers, Daniel Ma, Mabi Singh, Noam Yarom, Abdallah Sherif Radwan Mohamed, Katherine A Hutcheson, Stephen Y Lai, Clifton David Fuller
PURPOSE: Osteoradionecrosis of the jaw (ORNJ) is a severe iatrogenic disease characterized by bone death after radiation therapy (RT) to the head and neck. With over 9 published definitions and at least 16 diagnostic/staging systems, the true incidence and severity of ORNJ are obscured by lack of a standard for disease definition and severity assessment, leading to inaccurate estimation of incidence, reporting ambiguity, and likely under-diagnosis worldwide. This study aimed to achieve consensus on an explicit definition and phenotype of ORNJ and related precursor states through data standardization to facilitate effective diagnosis, monitoring, and multidisciplinary management of ORNJ...
April 9, 2024: medRxiv
#2
JOURNAL ARTICLE
Amani Kais, Stell Patadji Santiago, Peng Cheng Han, David A Clump, William A Stokes, Tanya Fancy, Ruifeng Cui, Elizabeth Martin, Meghan T Turner
INTRODUCTION: Neck mass is the most common presentation of human papillomavirus-related (HPV-related) oropharyngeal squamous cell carcinoma (OPSCC). Recently, circulating tumor HPV-DNA (ctHPVDNA) assays have been developed to detect active OPSCC. This pilot study investigates the diagnostic accuracy of ctHPVDNA in establishing HPV status for known vs. unknown OPSCC presenting as a neck mass. METHODS: A single-institution pilot study was conducted on all patients with OPSCC presenting as a neck mass between 2021 and 2022...
2024: Frontiers in Oncology
#3
JOURNAL ARTICLE
M Polack, M A Smit, G W van Pelt, A G H Roodvoets, E Meershoek-Klein Kranenbarg, H Putter, H Gelderblom, A S L P Crobach, V Terpstra, G Petrushevska, G Gašljević, S Kjær-Frifeldt, E M V de Cuba, N W J Bulkmans, G R Vink, R Al Dieri, R A E M Tollenaar, J H J M van Krieken, W E Mesker
BACKGROUND: The TNM (tumor-node-metastasis) Evaluation Committee of Union for International Cancer Control (UICC) and College of American Pathologists (CAP) recommended to prospectively validate the cost-effective and robust tumor-stroma ratio (TSR) as an independent prognostic parameter, since high intratumor stromal percentages have previously predicted poor patient-related outcomes. PATIENTS AND METHODS: The 'Uniform Noting for International application of Tumor-stroma ratio as Easy Diagnostic tool' (UNITED) study enrolled patients in 27 participating centers in 12 countries worldwide...
April 12, 2024: ESMO Open
#4
JOURNAL ARTICLE
Maria T Bourlon, Ami S Bhatt, Gilberto Lopes, Fredrick Chite Asirwa, Alexandru E Eniu, Patrick J Loehrer, Lawrence N Shulman, Julia Close, Jamie Von Roenn, Michal Tibbits, Doug Pyle, Julie R Gralow
Recognizing the rising incidence, prevalence, and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has committed to expanding its engagement at a global level. In 2017, the ASCO Academic Global Oncology Task Force sought to define the potential role for ASCO in supporting global oncology as an academic field. A set of recommendations to advance the status of global oncology as an academic discipline were created through a consensus-based process involving participation by a diverse group of global oncology and global health practitioners; these recommendations were then published...
April 2024: JCO global oncology
#5
JOURNAL ARTICLE
Roberta Caputo, Giuseppe Buono, Michela Piezzo, Claudia Martinelli, Daniela Cianniello, Alessandro Rizzo, Francesco Pantano, Nicoletta Staropoli, Rodolfo Cangiano, Salvatore Turano, Ida Paris, Francesco Nuzzo, Alessandra Fabi, Michelino De Laurentiis
OBJECTIVE: The objective of this multicenter, observational, retrospective analysis was to evaluate the safety and efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) patients managed according to common clinical practice in Italy. METHODS: Data were retrieved by 7 sites. Triple-negative BC was defined by the lack of expression of estrogen receptor (ER <1%), progesterone receptor (PgR <1%) and human-epidermal growth factor receptor-2 (HER2 0, 1+, 2+ ISH-not amplified) according to standard ASCO-CAP criteria...
2024: Frontiers in Oncology
#6
REVIEW
Samantha K F Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C Y Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J Gralla, Terry L Ng, Katarzyna J Jerzak
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking...
April 10, 2024: Supportive Care in Cancer
#7
JOURNAL ARTICLE
Susan Prendeville, Harpreet Kaur, Shervin Ansari, Shifaa Alqaqa, Tracy L Stockley, Katherine Lajkosz, Theodorus van der Kwast, Carol C Cheung, Shamini Selvarajah
Somatic tumor testing in prostate cancer (PCa) can guide treatment options by identifying clinically actionable variants in DNA damage repair (DDR) genes, including acquired variants not detected by germline testing alone. Guidelines currently recommend performing somatic tumor testing in metastatic PCa, while there is no consensus on the role of testing in regional disease and the optimal testing strategy is involving. This study evaluates the frequency, distribution, and pathologic correlates of somatic DDR mutations in metastatic and localized PCa following the implementation of pathologist-driven reflex testing at diagnosis...
April 6, 2024: Modern Pathology
#8
JOURNAL ARTICLE
Dwight H Owen, Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Narjust Florez, Sonum Puri, Erin L Schenk, Bryan J Schneider, Jyoti D Patel
No abstract text is available yet for this article.
April 8, 2024: JCO oncology practice
#9
JOURNAL ARTICLE
Ushna Zameer, Wajiha Shaikh, Abdul Moiz Khan
Lung cancer imposes a burden on the health care system worldwide affecting 2 million people and causing 1.8 million deaths in 2021.More than 85% of all lung cancer cases are reported under Non-small-cell lung cancer (NSCLC). It is critical to discover gene alterations to treat non-small cell lung cancer successfully. The CAP/IASLC/AMP recommendations supported use of polymerase chain reaction (PCR) and fluorescent in situ hybridization (FISH) EGFR (epidermal growth factor receptor) mutations and ALK (Anaplastic lymphoma kinase) rearrangements, respectively...
2024: Cancer Informatics
#10
REVIEW
Jacqueline K Perez, Jeanene Kleber, Michael Rothe, Pam Mangat, Elizabeth Garrett-Mayer, Richard L Schilsky
PURPOSE: With the advent of precision medicine, molecular tumor boards (MTBs) were established to interpret genomic results and guide decision making for targeted therapy in oncology patients. There are currently no universal guidelines for how MTBs should operate and thus variance can be seen depending on which MTB is reviewing the case. This study assesses the concordance of MTB recommendations when a participant case is reviewed by two different MTBs, establishes potential reasons for discordance, and advocates for the establishment of standard MTB operating guidelines...
March 2024: JCO Precision Oncology
#11
REVIEW
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock
Extracellular RNA (cell-free RNA; exRNA) from blood-derived liquid biopsies is an appealing, minimally invasive source of disease biomarkers. As pre-analytical variables strongly influence exRNA measurements, their reporting is essential for meaningful interpretation and replication of results. The aim of this review was to chart to what extent pre-analytical variables are documented, to pinpoint shortcomings and to improve future reporting. In total, 200 blood plasma exRNA studies published in 2018 or 2023 were reviewed for annotation of 22 variables associated with blood collection, plasma preparation, and RNA purification...
April 2, 2024: Molecular Oncology
#12
JOURNAL ARTICLE
Katleen Nobbe, Melanie Erices-Leclercq, Frank Foerster, Robert Förster, Stephan E Baldus, Christian Rudlowski, Lars Schröder, Sabine Lubig
PURPOSE: The introduction of HER2-targeting antibody drug conjugates (ADCs) offers new treatment options for female breast cancer patients (FBC) expressing low levels of HER2 (HER2 low). No evidence was found that HER2 low describes a new FBC subtype. There is a lack of studies determining the impact of HER2 low in male breast cancer (MBC). In this study, we evaluate the prevalence of HER2 low in primary MBC and correlate the results with patient characteristics. PATIENTS AND METHODS: In this study, histological specimens were obtained from 120 male patients diagnosed and treated for primary invasive breast cancer from 1995 to 2022 at Breast Cancer Units in Bergisch Gladbach, Chemnitz, and Zwickau, Germany...
2024: Breast Cancer: Targets and Therapy
#13
JOURNAL ARTICLE
Rania Chehade, Sharon Nofech-Mozes, Anna Plotkin, Kevin Yijun Fan, Sunit Das, Arjun Sahgal, Veronika Moravan, Katarzyna Joanna Jerzak
PURPOSE: Trastuzumab deruxtecan is a new treatment option for patients with advanced human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC). Although HER2-low status has been characterized in early and advanced BC, it has yet to be fully characterized in brain metastases (BrM). METHODS: Patients who underwent surgery for BC BrM at Sunnybrook Health Sciences Centre and for whom HER2 status was available on resected BrM were studied. Estrogen receptor, progesterone receptor, and HER2 status were assessed on the basis of ASCO/College of American Pathologists (CAP) guidelines...
March 2024: JCO Precision Oncology
#14
JOURNAL ARTICLE
Emma L Herbach, Michaela Curran, Mya L Roberson, Ryan M Carnahan, Bradley D McDowell, Kai Wang, Ingrid Lizarraga, Sarah H Nash, Mary Charlton
PURPOSE: To examine racial-ethnic variation in adherence to established quality metrics (NCCN guidelines and ASCO quality metrics) for breast cancer, accounting for individual-, facility-, and area-level factors. METHODS: Data from women diagnosed with invasive breast cancer at 66+ years of age from 2000 to 2017 were examined using SEER-Medicare. Associations between race and ethnicity and guideline-concordant diagnostics, locoregional treatment, systemic therapy, documented stage, and oncologist encounters were estimated using multilevel logistic regression models to account for clustering within facilities or counties...
March 28, 2024: Cancer Causes & Control: CCC
#15
JOURNAL ARTICLE
Alejandra Castanon, Benjamin D Bray, Sreeram V Ramagopalan
In this latest update we discuss real-world evidence (RWE) guidance from the leading oncology professional societies, the American Society of Clinical Oncology and the European Society for Medical Oncology, and the PRINCIPLED practical guide on the design and analysis of causal RWE studies.
March 28, 2024: Journal of Comparative Effectiveness Research
#16
JOURNAL ARTICLE
Dechuang Jiao, Guangyu Li, Hao Dai, Jia Wang, Jiao Zhang, Yangyang Hou, Xuhui Guo, Yajie Zhao, Xilong Gong, Zhenzhen Liu
BACKGROUND: According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, both immunohistochemical HER2 (3+) and HER2 (2+)/in situ hybridization (ISH) amplified [HER2 (2+)/ISH+] breast cancers (BCs) fall under the HER2-positive BC category. However, there is a lack of studies exploring the difference of neoadjuvant therapeutic response between patients with HER2 (3+) and HER2 (2+)/ISH+ early BC. We aimed to evaluate the neoadjuvant therapeutic response, long-term outcome, and intrinsic subtype heterogeneity between HER2 (3+) and HER2 (2+)/ISH+ BC...
March 27, 2024: Oncologist
#17
JOURNAL ARTICLE
Hong Xiao, Riha Vaidya, Dawn L Hershman, Joseph M Unger
PURPOSE: In October 2017, an ASCO, Friends of Cancer Research (FoCR), and US Food and Drug Administration (ASCO/FoCR/FDA) task force recommended that common eligibility criteria be modified to make trials more inclusive. We examined whether patterns of exclusions regarding patients with brain metastases changed over time in relation to these recommendations. METHODS: Trial eligibility criteria were abstracted from ClinicalTrials.gov for phase I-III US-based interventional clinical trials for patients with advanced breast, colorectal, lung, or melanoma cancers from January 2012 to December 2022...
March 27, 2024: Journal of Clinical Oncology
#18
JOURNAL ARTICLE
Mary C Boulanger, Margaret D Krasne, Ethan K Gough, Samantha Myers, Ilene S Browner, Josephine L Feliciano
Although cancer care is often contextualized in terms of survival, there are other important cancer care outcomes, such as quality of life and cost of care. The ASCO Value Framework assesses the value of cancer therapies not only in terms of survival but also with consideration of quality of life and financial cost. Early palliative care for patients with advanced cancer is associated with improved quality of life, mood, symptoms, and overall survival for patients, as well as cost savings. While palliative care has been shown to have numerous benefits, the impact of real-world implementation of outpatient embedded palliative care on value-based metrics is not fully understood...
March 7, 2024: Current Oncology
#19
JOURNAL ARTICLE
Ushang Kate, Anurita Pais, Neelam Kamble, Sandhya Kandoor, Kunal Sharma
Breast cancer patients with HER2 gene amplification as assessed by FISH are eligible for HER2-targeted therapy. However, in a small subset of patients, unusual FISH pattern of co-localization and co-amplification can pose challenges in interpretation of the HER2 status and hence to assess the HER2 status accurately; our aim was to report their incidence and analyze them based on latest ASCO/CAP 2018 guidelines. We present seven cases with HER2/CEP17 co-amplification and co-localization from a total 4040 cases referred during the year 2017 to 2021 at Mumbai Reference Laboratory, SRL Diagnostics...
March 2024: Indian Journal of Surgical Oncology
#20
JOURNAL ARTICLE
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, Eliza Beal, Richard S Finn, Terence P Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O Kaseb, R Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M Remak, Davendra P S Sohal, Tamar H Taddei, Andrea Wilson Woods, Mark Yarchoan, Michal G Rose
PURPOSE: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. RESULTS: Ten new RCTs met the inclusion criteria and were added to the evidence base...
March 19, 2024: Journal of Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
